{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:03:22Z","timestamp":1773086602377,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005247","name":"University of British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018911","name":"University Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000261","name":"Multiple Sclerosis Society of Canada","doi-asserted-by":"publisher","award":["2302"],"award-info":[{"award-number":["2302"]}],"id":[{"id":"10.13039\/501100000261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jocn.2025.111493","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T12:24:57Z","timestamp":1754396697000},"page":"111493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A broad range of antiphospholipid IgM are elevated across different multiple sclerosis clinical phenotypes"],"prefix":"10.1016","volume":"140","author":[{"given":"Kaya","family":"Frese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Becquart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Carruthers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Traboulsee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana-Luiza","family":"Sayao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Schabas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.R.Wayne","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene M.","family":"Vavasour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve E.","family":"Kalloger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Laule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline A.","family":"Quandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jocn.2025.111493_b0005","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","article-title":"Multiple sclerosis: mechanisms and immunotherapy","volume":"97","author":"Baecher-Allan","year":"2018","journal-title":"Neuron"},{"issue":"8","key":"10.1016\/j.jocn.2025.111493_b0010","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"J Am Med Assoc"},{"issue":"7","key":"10.1016\/j.jocn.2025.111493_b0015","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/brain\/awy151","article-title":"The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells","volume":"141","author":"Machado-Santos","year":"2018","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.jocn.2025.111493_b0020","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"\u201cDefining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis,\u201d (in eng)","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jocn.2025.111493_b0025","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"\u201cDefining the clinical course of multiple sclerosis: the 2013 revisions,\u201d (in eng)","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2025.111493_b0030","doi-asserted-by":"crossref","unstructured":"H. Lassmann, \u201cPathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis,\u201d (in English), Frontiers in Immunology, Review vol. 9, no. 3116, 2019-January-10 2019, doi: 10.3389\/fimmu.2018.03116.","DOI":"10.3389\/fimmu.2018.03116"},{"issue":"9","key":"10.1016\/j.jocn.2025.111493_b0035","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028928","article-title":"Clinical Course of Multiple Sclerosis","volume":"8","author":"Klineova","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"10.1016\/j.jocn.2025.111493_b0040","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3390\/cells9040812","article-title":"\u201cMyelin Fat Facts: an Overview of Lipids and Fatty Acid Metabolism,\u201d (in eng)","volume":"9","author":"Poitelon","year":"2020","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.jocn.2025.111493_b0045","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/jnr.24062","article-title":"Multiple sclerosis: Presence of serum antibodies to lipids and predominance of cholesterol recognition","volume":"95","author":"Jurewicz","year":"2017","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.jocn.2025.111493_b0050","article-title":"Antiphospholipid Antibodies Overlapping in Isolated Neurological Syndrome and Multiple Sclerosis: Neurobiological Insights and Diagnostic challenges","volume":"13","author":"D\u2019Angelo","year":"2019","journal-title":"(in English), Frontiers in Cellular Neuroscience, Review"},{"issue":"1","key":"10.1016\/j.jocn.2025.111493_b0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/brainsci12010091","article-title":"Neuropsychiatric Manifestations of Antiphospholipid Syndrome\u2014A Narrative Review","volume":"12","author":"Man","year":"2022","journal-title":"Brain Sci"},{"key":"10.1016\/j.jocn.2025.111493_b0060","unstructured":"Q. R. Morell P, \u201cCharacteristic Composition of Myelin,\u201d in Basic neurochemistry: molecular, cellular, and medical aspects, A. B. Siegel GJ, Albers RW, et al. Ed., 6th ed. no. Book, Whole). Philadelphia: Lippincott Williams & Wilkins, 1999."},{"key":"10.1016\/j.jocn.2025.111493_b0065","doi-asserted-by":"crossref","unstructured":"L. F. Eng, F. C. Chao, B. Gerstl, D. Pratt, and M. G. Tavaststjerna, \u201cThe maturation of human white matter myelin. Fractionation of the myelin membrane proteins,\u201d (in eng), Biochemistry, vol. 7, no. 12, pp. 4455-65, Dec 1968, doi: 10.1021\/bi00852a042.","DOI":"10.1021\/bi00852a042"},{"key":"10.1016\/j.jocn.2025.111493_b0070","doi-asserted-by":"crossref","unstructured":"J. S. O'brien and E. L. Sampson, \u201cLipid composition of the normal human brain: gray matter, white matter, and myelin,\u201d Journal of lipid research, vol. 6 4, pp. 537-44, 1965.","DOI":"10.1016\/S0022-2275(20)39619-X"},{"issue":"3","key":"10.1016\/j.jocn.2025.111493_b0075","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF03160049","article-title":"\u201cLipid abnormalities in the brain in adult Down's syndrome and Alzheimer's disease,\u201d (in eng)","volume":"11","author":"Brooksbank","year":"1989","journal-title":"Mol Chem Neuropathol"},{"issue":"2","key":"10.1016\/j.jocn.2025.111493_b0080","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0378-4347(95)00576-5","article-title":"\u201cHigh-performance liquid chromatography method with light-scattering detection for measurements of lipid class composition: analysis of brains from alcoholics,\u201d (in eng)","volume":"681","author":"Olsson","year":"1996","journal-title":"J Chromatogr B Biomed Appl"},{"issue":"4","key":"10.1016\/j.jocn.2025.111493_b0085","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2217\/17460875.2.4.403","article-title":"\u201cRole of Lipids in Brain Injury and Diseases,\u201d (in eng)","volume":"2","author":"Adibhatla","year":"2007","journal-title":"Future Lipidol"},{"key":"10.1016\/j.jocn.2025.111493_b0090","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cca.2019.04.065","article-title":"Clinical performance of non-criteria antibodies to phospholipids in chinese patients with antiphospholipid syndrome","volume":"495","author":"Zhang","year":"2019","journal-title":"Clin Chim Acta"},{"issue":"21","key":"10.1016\/j.jocn.2025.111493_b0095","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"\u201cDiagnosis and Management of the Antiphospholipid Syndrome,\u201d (in eng)","volume":"378","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2025.111493_b0100","doi-asserted-by":"crossref","unstructured":"T. Koudriavtseva, G. D\u2019Agosto, C. Mandoj, I. Sperduti, and P. Cordiali-Fei, \u201cHigh frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory\u2013thrombotic processes,\u201d Neurological Sciences, vol. 35, no. 11, pp. 1737-1741, 2014-11-01 2014, doi: 10.1007\/s10072-014-1823-4.","DOI":"10.1007\/s10072-014-1823-4"},{"issue":"9","key":"10.1016\/j.jocn.2025.111493_b0105","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0248-8663(99)80042-3","article-title":"\u201c[Multiple sclerosis and antiphospholipid antibodies: study of 62 consecutive patients],\u201d (in fre)","volume":"19","author":"Cordoliani","year":"1998","journal-title":"Rev Med Interne"},{"issue":"2","key":"10.1016\/j.jocn.2025.111493_b0110","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1191\/096120399678847461","article-title":"Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS?","volume":"8","author":"Ijdo","year":"1999","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.jocn.2025.111493_b0115","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1620\/tjem.178.203","article-title":"\u201cCharacterization of serum anti-phospholipid antibodies in patients with multiple sclerosis,\u201d (in eng)","volume":"178","author":"Sugiyama","year":"1996","journal-title":"Tohoku J Exp Med"},{"issue":"1\u20132","key":"10.1016\/j.jocn.2025.111493_b0120","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jneuroim.2007.04.008","article-title":"\u201cClinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients,\u201d (in eng)","volume":"187","author":"Garg","year":"2007","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jocn.2025.111493_b0125","article-title":"Evaluation of the Diagnostic Value of Non-criteria Antibodies for Antiphospholipid Syndrome patients in a Chinese Cohort","volume":"12","author":"Hu","year":"2021","journal-title":"(in English), Frontiers in Immunology, Original Research"},{"key":"10.1016\/j.jocn.2025.111493_b0130","article-title":"\u201cNon-criteria antiphospholipid antibodies in antiphospholipid syndrome: Diagnostic value added,\u201d (in eng)","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jocn.2025.111493_b0135","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"The Lancet Neurology"},{"issue":"3","key":"10.1016\/j.jocn.2025.111493_b0140","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1600-0404.1993.tb04214.x","article-title":"\u201cAnticardiolipin antibodies in Japanese patients with multiple sclerosis,\u201d (in eng)","volume":"88","author":"Fukazawa","year":"1993","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"10.1016\/j.jocn.2025.111493_b0145","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2377-7-36","article-title":"Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study","volume":"7","author":"Bidot","year":"2007","journal-title":"BMC Neurol"},{"issue":"2","key":"10.1016\/j.jocn.2025.111493_b0150","first-page":"313","article-title":"\u201cAnti-cardiolipin antibodies in neurological disorders: cross-reaction with anti-single stranded DNA activity,\u201d (in eng)","volume":"68","author":"Cola\u00e7o","year":"1987","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"10.1016\/j.jocn.2025.111493_b0155","first-page":"559","article-title":"\u201cPrevalence of Classic and Non-Classic Antiphospholipid Antibodies in Multiple Sclerosis,\u201d (in eng)","volume":"17","author":"Shor","year":"2015","journal-title":"Isr Med Assoc J"},{"issue":"1\u20132","key":"10.1016\/j.jocn.2025.111493_b0160","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jneuroim.2012.03.020","article-title":"\u201cAxonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions,\u201d (in eng)","volume":"247","author":"S\u00e1daba","year":"2012","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.jocn.2025.111493_b0165","doi-asserted-by":"crossref","first-page":"11826","DOI":"10.1038\/ncomms11826","article-title":"Long-lived antigen-induced IgM plasma cells demonstrate somatic mutations and contribute to long-term protection","volume":"7","author":"Bohannon","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jocn.2025.111493_b0170","first-page":"37","article-title":"Immunoglobulins: structure and function","volume":"4","author":"Frazer","year":"1999","journal-title":"Fundamental immunology"},{"key":"10.1016\/j.jocn.2025.111493_b0175","doi-asserted-by":"crossref","unstructured":"M. C. S\u00e1daba et al., \u201cSerum antibodies to phosphatidylcholine in MS,\u201d (in eng), Neurol Neuroimmunol Neuroinflamm, vol. 7, no. 4, Jul 2020, doi: 10.1212\/nxi.0000000000000765.","DOI":"10.1212\/NXI.0000000000000765"},{"key":"10.1016\/j.jocn.2025.111493_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2019.101017","article-title":"The highly unnatural fatty acid profile of cells in culture","volume":"77","author":"Else","year":"2020","journal-title":"Prog Lipid Res"},{"issue":"12","key":"10.1016\/j.jocn.2025.111493_b0185","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.3390\/nu14122495","article-title":"Changes in Phospholipid Composition of the Human Cerebellum and Motor Cortex during Normal Ageing","volume":"14","author":"Hancock","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.jocn.2025.111493_bib271","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2020.108672","article-title":"Serum phospholipidomics reveals altered lipid profile and promising biomarkers in multiple sclerosis","volume":"697","author":"Ferreira","year":"2021","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.jocn.2025.111493_bib272","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/metabo10090366","article-title":"Lipidomic UPLC-MS\/MS Profiles of Normal-Appearing White Matter Differentiate Primary and Secondary Progressive Multiple Sclerosis","volume":"10","author":"Pousinis","year":"2020","journal-title":"Metabolites"},{"key":"10.1016\/j.jocn.2025.111493_b0190","doi-asserted-by":"crossref","unstructured":"\u00da. Mu\u00f1oz et al., \u201cSerum levels of IgM to phosphatidylcholine predict the response of multiple sclerosis patients to natalizumab or IFN-\u03b2,\u201d (in eng), Sci Rep, vol. 12, no. 1, p. 13357, Aug 3 2022, doi: 10.1038\/s41598-022-16218-y.","DOI":"10.1038\/s41598-022-16218-y"},{"issue":"1","key":"10.1016\/j.jocn.2025.111493_b0195","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00415-009-5264-6","article-title":"MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis","volume":"257","author":"Stosic","year":"2010","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2025.111493_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103269","article-title":"\u201cElevated levels of serum CD5 antigen-like protein distinguish secondary progressive multiple sclerosis from other disease subtypes,\u201d (in eng)","volume":"56","author":"Kamma","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jocn.2025.111493_b0205","doi-asserted-by":"crossref","unstructured":"L. Sanchez-Moral, N. R\u00e0fols, C. Martori, T. Paul, \u00c9. T\u00e9llez, and M. R. Sarrias, \u201cMultifaceted Roles of CD5L in Infectious and Sterile Inflammation,\u201d (in eng), Int J Mol Sci, vol. 22, no. 8, Apr 15 2021, doi: 10.3390\/ijms22084076.","DOI":"10.3390\/ijms22084076"},{"issue":"4","key":"10.1016\/j.jocn.2025.111493_b0210","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.celrep.2013.03.006","article-title":"\u201cObesity-associated autoantibody production requires AIM to retain the immunoglobulin M immune complex on follicular dendritic cells,\u201d (in eng)","volume":"3","author":"Arai","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.jocn.2025.111493_b0215","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.neulet.2015.08.054","article-title":"Anti-annexin antibodies, cholesterol levels and disability in multiple sclerosis","volume":"606","author":"Mandoj","year":"2015","journal-title":"Neurosci Lett"},{"issue":"4","key":"10.1016\/j.jocn.2025.111493_b0220","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/0961203311427550","article-title":"Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis","volume":"21","author":"Szmyrka-Kaczmarek","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.jocn.2025.111493_b0225","doi-asserted-by":"crossref","unstructured":"O. Heinzlef, \u201cAnticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics,\u201d Journal of Neurology, Neurosurgery & Psychiatry, vol. 72, no. 5, pp. 647-649, 2002-05-01 2002, doi: 10.1136\/jnnp.72.5.647.","DOI":"10.1136\/jnnp.72.5.647"},{"issue":"3","key":"10.1016\/j.jocn.2025.111493_b0230","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/jaut.2000.0367","article-title":"Prevalence and Clinical significance of Anti-phospholipid Antibodies in Multiple Sclerosis: a Study of 89 patients","volume":"14","author":"Roussel","year":"2000","journal-title":"J Autoimmun"},{"issue":"5","key":"10.1016\/j.jocn.2025.111493_b0235","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1034\/j.1600-0404.2002.01161.x","article-title":"\u201cImmunoserological changes in the cerebro-spinal fluid and serum in systemic lupus erythematosus patients with demyelinating syndrome and multiple sclerosis,\u201d (in eng)","volume":"105","author":"Baraczka","year":"2002","journal-title":"Acta Neurol Scand"},{"issue":"8","key":"10.1016\/j.jocn.2025.111493_b0240","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1179\/1743132812Y.0000000076","article-title":"Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study","volume":"34","author":"Zivadinov","year":"2012","journal-title":"Neurol Res"},{"issue":"1","key":"10.1016\/j.jocn.2025.111493_b0245","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nm1344","article-title":"Lipid microarrays identify key mediators of autoimmune brain inflammation","volume":"12","author":"Kanter","year":"2006","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.jocn.2025.111493_b0250","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/0896-8411(92)90193-T","article-title":"Phospholipid specificity and requirement of \u03b22-glycoprotein-I for reactivity of antibodies from patients with primary antiphospholipid syndrome","volume":"5","author":"Cabral","year":"1992","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jocn.2025.111493_b0255","article-title":"\u201cPrevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in chinese patients,\u201d (in eng)","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.jocn.2025.111493_b0260","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/ejlt.200700024","article-title":"The functional role of sphingomyelin in cell membranes","volume":"109","author":"Slotte","year":"2007","journal-title":"Eur J Lipid Sci Technol"},{"issue":"4","key":"10.1016\/j.jocn.2025.111493_b0265","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/jnc.15133","article-title":"The role of Sphingolipids in myelination and myelin stability and their involvement in childhood and adult demyelinating disorders","volume":"156","author":"Giussani","year":"2021","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.jocn.2025.111493_b0270","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41582-021-00581-x","article-title":"\u201cMechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis,\u201d (in eng)","volume":"18","author":"Yong","year":"2022","journal-title":"Nat Rev Neurol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825004667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825004667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:38:55Z","timestamp":1760139535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586825004667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":56,"alternative-id":["S0967586825004667"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111493","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A broad range of antiphospholipid IgM are elevated across different multiple sclerosis clinical phenotypes","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111493","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111493"}}